DelveInsight’s, “Ataxia telangiectasia - Pipeline Insight, 2021,” report provides comprehensive insights about 6+ companies and 6+ pipeline drugs in Ataxia telangiectasia pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Geography Covered
• Global coverage

Ataxia telangiectasia Understanding
Ataxia telangiectasia: Overview
Ataxia-telangiectasia is a rare inherited disorder that affects the nervous system, immune system, and other body systems. The disease is characterized by progressive difficulty with coordinating movements (ataxia) beginning in early childhood. Affected children typically develop difficulty in walking, problems with balance and hand coordination, involuntary jerking movements (chorea), muscle twitches (myoclonus), and disturbances in nerve function (neuropathy). Ataxia-telangiectasia is inherited in an autosomal recessive pattern. A diagnosis of ataxia telangiectasia is made based upon a detailed patient history, a thorough clinical evaluation, identification of characteristic symptoms, and a variety of specialized tests including blood tests, magnetic resonance imaging (MRI), and karyotyping. Treatment for AT is directed toward control of symptoms. For respiratory infections, therapy with an antibiotic drug, postural drainage (with the head lower than the rest of the body) of the bronchial tubes and lungs, and gammaglobulin injections in some cases may be effective.

"Ataxia telangiectasia - Pipeline Insight, 2021" report by DelveInsight outlays comprehensive insights of present scenario and growth prospects across the indication. A detailed picture of the Ataxia telangiectasia pipeline landscape is provided which includes the disease overview and Ataxia telangiectasia treatment guidelines. The assessment part of the report embraces, in depth Ataxia telangiectasia commercial assessment and clinical assessment of the pipeline products under development. In the report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Ataxia telangiectasia collaborations, licensing, mergers and acquisition, funding, designations and other product related details.

Report Highlights
• The companies and academics are working to assess challenges and seek opportunities that could influence Ataxia telangiectasia R&D. The therapies under development are focused on novel approaches to treat/improve Ataxia telangiectasia.

Ataxia telangiectasia Emerging Drugs Chapters
This segment of the Ataxia telangiectasia report encloses its detailed analysis of various drugs in different stages of clinical development, including phase III, II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.

Ataxia telangiectasia Emerging Drugs
• IB1001: IntraBio
IB1001 (N-Acetyl-L-Leucine) is an orally administered small molecule, calcium channel modulator and modified amino acid. IntraBio is developing IB1001 for other neurodegenerative diseases and lysosomal storage disorders. The drug is in Phase II clinical studies for the treatment of Ataxia Telangiectasia.

• Ery-Dex: EryDel
Ery-Dex is a novel, proprietary method of encapsulating a potent steroid, dexamethasone sodium phosphate, in red blood cells allowing for its gradual dephosphorylation and release of dexamethasone in a patient’s circulation for up to 30 days, providing the potential for effective treatment and preventing the unacceptable systemic side effects of oral or intravenous steroid treatment. The drug is in Phase 3 clinical study for the treatment of Ataxia Telangiectasia patients.
Further product details are provided in the report……..

Ataxia telangiectasia: Therapeutic Assessment
This segment of the report provides insights about the different Ataxia telangiectasia drugs segregated based on following parameters that define the scope of the report, such as:
• Major Players in Ataxia telangiectasia
There are approx. 6+ key companies which are developing the therapies for Ataxia telangiectasia. The companies which have their Ataxia telangiectasia drug candidates in the most advanced stage, i.e. Phase III include, Orasis Pharmaceuticals.

• Phases
DelveInsight’s report covers around 6+ products under different phases of clinical development like
• Late stage products (Phase III)
• Mid-stage products (Phase II)
• Early-stage product (Phase I) along with the details of
• Pre-clinical and Discovery stage candidates
• Discontinued & Inactive candidates

• Route of Administration
Ataxia telangiectasia pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as
• Oral
• Parenteral
• Intravitreal
• Subretinal
• Topical

• Molecule Type
Products have been categorized under various Molecule types such as
• Monoclonal Antibody
• Peptides
• Polymer
• Small molecule
• Gene therapy

• Product Type
Drugs have been categorized under various product types like Mono, Combination and Mono/Combination.

Ataxia telangiectasia: Pipeline Development Activities
The report provides insights into different therapeutic candidates in phase III, II, I, preclinical and discovery stage. It also analyses Ataxia telangiectasia therapeutic drugs key players involved in developing key drugs.

Pipeline Development Activities
The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Ataxia telangiectasia drugs.

Ataxia telangiectasia Report Insights
• Ataxia telangiectasia Pipeline Analysis
• Therapeutic Assessment
• Unmet Needs
• Impact of Drugs

Ataxia telangiectasia Report Assessment
• Pipeline Product Profiles
• Therapeutic Assessment
• Pipeline Assessment
• Inactive drugs assessment
• Unmet Needs

Key Questions
Current Treatment Scenario and Emerging Therapies:
• How many companies are developing Ataxia telangiectasia drugs?
• How many Ataxia telangiectasia drugs are developed by each company?
• How many emerging drugs are in mid-stage, and late-stage of development for the treatment of Ataxia telangiectasia?
• What are the key collaborations (Industry–Industry, Industry–Academia), Mergers and acquisitions, licensing activities related to the Ataxia telangiectasia therapeutics?
• What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?
• What are the clinical studies going on for Ataxia telangiectasia and their status?
• What are the key designations that have been granted to the emerging drugs?

Key Players
• IntraBio
• EryDel
• ChromaDex
• Grace Therapeutics

Key Products
• IB1001
• Ery-Dex
• Nicotinamide riboside
• Betamethasone oral spray